# US 2021/0260154 A1 · Methods for attenuating release of inflammatory mediators and peptides useful therein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260154 A1
- Document ID: US20210260154A1
- Status: Published application
- Kind: A1
- Application number: 17/307,471
- Filed: 2021-05-04
- Published: 2021-08-26
- Earliest claimed: 2006-07-26
- Assignees: Biomarck Pharmaceuticals, Ltd.
- Applicants: Biomarck Pharmaceuticals Ltd.
- Inventors: Indu PARIKH
- Web page: https://patentgrep.com/patent/US20210260154A1

## CPC

- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/10: Anti-acne agents
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.

## Claims

### Claim 1

A method for inhibiting the production of one or more inflammatory mediators from an inflammatory cell in a tissue and/or fluid of a subject, the method comprising administering to the subject an effective amount of a peptide comprising an amino acid sequence selected from the group consisting of: SEQ ID NOs: 106, 1, 11, 37, 45, 79, 91, 93, 108, 121, 124, 141, 143, 153, 219, 234, 239, 248, 241, and 251, wherein the N-terminal amino acid of the peptide is chemically modified by acetylation, and wherein the one or more inflammatory mediators are IL-1beta, IL-8, TNFalpha, or a combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has a respiratory disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein the respiratory disease is asthma, chronic bronchitis, chronic obstructive respiratory disease, or acute respiratory distress syndrome (ARDS).

### Claim 4 (depends on 1)

The method of claim 1, wherein the peptide is administered by inhalation, pulmonary administration, or nasal administration.

### Claim 5 (depends on 1)

The method of claim 1, wherein the peptide is administered in the form of an aerosol.

### Claim 6 (depends on 1)

The method of claim 1, wherein the peptide is administered in the form of a dry powder.

### Claim 7 (depends on 1)

The method of claim 1, wherein the peptide is administered by a dry powder inhaler, metered dose inhaler, or nebulizer.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 9 (depends on 1)

The method of claim 1, further comprising administering to the subject a second therapeutic agent selected from the group consisting of an antibiotic, an antiviral compound, an antiparasitic compound, an anti-inflammatory compound, and an immunomodulator.

### Claim 10 (depends on 1)

The method of claim 1, wherein said peptide consists of acetyl-peptide 106 (SEQ ID NO: 106).
